Aadi appoints Dave Lennon as President and CEO; base salary $640K, option for 490K shares

Whitehawk Therapeutics, Inc.

David J. Lennon appointed President and CEO, effective Oct 2, 2023; Scott Giacobello returns to CFO role.
Compensation: $640,000 base salary, up to 60% annual bonus, $240,000 sign-on (cash + RSUs), option for 490,000 shares.
Board increased from 8 to 9; Lennon appointed as Class II director. Company adopted 2023 Inducement Plan reserving 600,000 shares.
Press release highlights Lennon’s Novartis background and FYARRO pipeline expansion into endometrial, neuroendocrine cancers.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

David J. Lennon

President and Chief Executive Officer

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2023-10-02
Filed: October 2, 2023, 7:59 PM ET

the Board of Directors (the “ Board ”) of Aadi Bioscience, Inc. (the “ Company ”) appointed David J. Lennon, Ph.D., to serve as the Company’s President and Chief Executive Officer and principal executive officer, effective as of October 2, 2023

Role change

Scott Giacobello

Chief Financial Officer

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2023-10-02
Filed: October 2, 2023, 7:59 PM ET

Mr. Giacobello has served as the Company’s Interim CEO and President and principal executive officer since March 15, 2023, and will continue to serve as the Company’s Chief Financial Officer, a position he has held since November 2021, following Dr. Lennon’s appointment.

Appointed

David J. Lennon

Class II Director

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2023-10-02
Filed: October 2, 2023, 7:59 PM ET

the Board increased the Board’s size from eight (8) to nine (9) directors and appointed Dr. Lennon to fill the resulting vacancy

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Lennon was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

the Board of Directors (the “ Board ”) of Aadi Bioscience, Inc. (the “ Company ”) appointed David J. Lennon, Ph.D., to serve as the Company’s President and Chief Executive Officer and principal executive officer, effective as of October 2, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Giacobello changed role as Chief Financial Officer at Whitehawk Therapeutics, Inc..

Action: continued
Role: Chief Financial Officer

Exact text from the filing

Mr. Giacobello has served as the Company’s Interim CEO and President and principal executive officer since March 15, 2023, and will continue to serve as the Company’s Chief Financial Officer, a position he has held since November 2021, following Dr. Lennon’s appointment.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

David J. Lennon was appointed as Class II Director at Whitehawk Therapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

the Board increased the Board’s size from eight (8) to nine (9) directors and appointed Dr. Lennon to fill the resulting vacancy

View on SEC.gov

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-248461

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.